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ew Insights on
ndothelial Progenitor
ell Subpopulations and
heir Angiogenic Properties*
duard Shantsila, MD,†
imothy Watson, MRCP,† Hung-Fat Tse, MD,‡
regory Y. H. Lip, MD†
irmingham, United Kingdom;
nd Hong Kong, China
n 1997, Asahara et al. (1) reported the isolation of putative
ndothelial progenitor cells (EPCs) from human peripheral
lood, on the basis of cell surface expression of both
ematopoietic stem cell (CD34) and kinase insert domain
eceptor (KDR) markers. They observed that these cells
ifferentiate into endothelial cells in vitro and in vivo. These
ells have opened new perspectives for “regenerative” cardi-
logical interventions, and EPCs have since attracted much
nterest with many studies demonstrating strong association
etween the quantity/function of such cells and different
spects of cardiovascular health (2–4).
See page 660
Enthusiasm for EPCs needs to be tempered by definition
f what EPCs are, as well as the availability of a reliable
ethod to assess their quantity and quality, functional
tatus, and therapeutic application. In particular, neither is
D34 a specific stem cell marker nor is KDR a specific
ature endothelial cell marker (Fig. 1). The search for more
pecific and reliable markers of “true” EPCs is therefore
ngoing. Consequently, an early hematopoietic stem cell
arker, CD133, was adopted as an alternative additional
arker to indicate “true” EPCs (5). The CD133 marker is
xpressed on hematopoietic stem cells and progenitor cells
rom human bone marrow, fetal liver, and peripheral blood
6). In culture, these cells grow endothelial cell colony-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Haemostasis, Thrombosis and Vascular Biology Unit, University
epartment of Medicine, City Hospital, Birmingham, United Kingdom; and thec
Cardiology Division, Department of Medicine, University of Hong Kong, Hong
ong, China.orming units (CFU-ECs), which are also referred to as
early endothelial colonies,” with rapid down-regulation of
D133 and acquisition of some mature endothelial markers
5). It was therefore proposed that CD133 might provide a
ore reliable means of defining and tracking human
ngioblast-like EPCs and distinguishing these from mature
ndothelial or monocytic cells. As a result, the combination
henotype of CD34/CD133/KDR is now commonly
sed as a definition for EPCs.
Nonetheless, EPC subpopulations may well display dif-
erent angiogenic properties. As highlighted in this issue of
he Journal, Sieveking et al. (7) provide new insights from a
ovel human angiogenesis assay, showing that although
resh EPCs can be directly incorporated into the endothelial
onolayer, other endothelial-like cells from CFU-ECs,
hen transplanted into ischemic tissues, they promote
ngiogenesis and are found around the neovasculature but
re not incorporated within it (7). These spindle-like cells
ppear to possess a relatively low proliferative capacity and a
ow ability to express mature endothelial proteins (8). The
xact mechanisms of their effects on cardiovascular health
re still poorly understood, with no evidence that these cells
re a major source of mature endothelial cells.
These important observations may make some previous
tudy results difficult to interpret, given that more than 1
ind of cell with angiogenic properties exist. This raises
ome controversy with respect to the identification and
rigin of isolated EPCs, because these cells seem to reflect
functional subpopulation within the blood mononuclear
ells that have the potential to differentiate into an endo-
helial phenotype in vivo.
As shown in Figure 1, the definition of EPCs by surface
arkers is challenging, given the change in surface marker
rofiles during the process of mobilization and maturation.
or example, CD34/133 progenitors differentiate into
D34/133 EPCs that possess more pronounced angio-
enic properties (9). Of note, no correlation was found
etween the number CD34 or CD133 circulating cells
nd the numbers of CFU-ECs (10). Moreover, erythrocyte
ysing before flow cytometry affects cell survival and has a
igh impact on the quantitative analysis of EPCs, with 20%
ower numbers compared with nonlyse protocols (11). In
ddition, other sorts of endothelial colonies can be grown.
or example, there are at least 2 morphologically and
unctionally distinct endothelial cell populations that can
robably be grown from circulating mononuclear cells: the
o-called “early” and “late” EPCs according to the timing of
heir emergence during culture. The early EPCs form the
ore conventional CFU-ECs, and late EPCs are thought
o represent those “outgrowth” endothelial cells (OECs) as
escribed by Sieveking et al. (7). Thus, the quantity and
unctional evaluation of putative endothelial progenitors
ay be problematic, owing to the low specificity of cellulture techniques.
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Editorial Comment February 12, 2008:669–71hat Are OECs?
he EPCs growing into OECs show high proliferative
otential and originate predominantly from bone marrow
onors. These are considered to be circulating angioblasts,
lthough relatively few studies have fully characterized their
roperties. The so-called “true” EPCs as estimated by flow
ytometry (i.e., CD34/CD133/KDR cells) yield the
ECs during cell culture. As shown in Figure 1, formation
f OEC colonies has been exclusively found in the CD34/
D133 selected cell population but not the CD34/
D133 or CD34/CD133 populations (12). The leu-
ocyte/monocyte antigens CD45 and CD14 were also
ot detectable in separated CD34/CD133 cells. In
nother study, only the small BM CD34/CD45 cell
raction, but not the CD34/CD45 hematopoietic
rogenitor fraction nor any other CD45 subpopulation,
Figure 1 Properties and Antigenic Cell Surface Markers
of Both “Early” EPCs and “Late” EPCs (OECs)
Note that continual maturation results in antigenic marker shift, and therefore
identification of subpopulations has often proved to be challenging. Also note
that that current endothelial progenitor cell (EPC) definitions are based predom-
inantly on phenotype. Early EPCs are, however readily identifiable by their abil-
ity to form colony-forming units on cell culture, whereas late EPCs are more
readily identifiable using flow cytometry. As cells continue to mature and inte-
grate into the endothelium, expression of CD31 and von Willebrand factor (vWf)
increases. OEC  outgrowth endothelial cell; KDR  kinase insert domain
receptor.ere able to grow OECs (13). Furthermore, OECs eenerating CD34/CD45 cells express KDR but not
D133, whereas CD34/CD45 hematopoietic progen-
tors express CD133 (13).
In contrast, early EPCs are considered to represent cells
f probable different lineage, which includes a subset of
D14/CD34 monocytic cells with the potential to
ifferentiate into endothelial-like cells and form CFU-ECs
nder certain environmental conditions (14). The available
ata suggest that CFU-ECs belong to the monocyte-
acrophage lineage, because they share many immunophe-
otypic and molecular features (15). In polycythemia rubra
era patients harboring a Janus kinase 2 V617F mutation in
ematopoietic stem cell clones, for example, CFU-ECs,
ere shown to possess myeloid progenitor cell activity, to
ifferentiate into phagocytic macrophages and to fail to
orm perfused vessels in vivo, strikingly in contrast to
ECs, which are clonally distinct from CFU-ECs (16).
hat Other Evidence
s There for Subtypes of EPCs?
hen a highly sensitive antibody-conjugated magnetofluo-
escent liposomes technique was used, Romagnani et al.
17) found a population of CD14/CD34low cells, which
epresented a variable proportion of CD14 cells and
onstituted the dominant population among circulating
DR cells. In that study, virtually all CD14 cells present
n the bone marrow were found to be CD14/CD34low
ouble-positive cells.
re These Differences Important?
lthough monocyte-derived EPCs have a lower in vitro
roliferation potential than hematopoietic stem cells or
ord-blood–derived EPCs, the different progenitor types
eem to have a similar ability to enhance neovascularization
n experimental models (18). One may speculate that
roliferative capacity is not the only decisive factor and that
he monocyte-derived EPCs are also likely to play an
mportant role in angiogenesis and arteriogenesis via a
aracrine effect with the release of growth factors, such as
ascular endothelial growth factor, as shown by Sieveking
t al. (7).
However, when human CD34 cells or CD14 cells
ere locally delivered into the ischemic limbs of diabetic
ice, CD14 cell therapy improved healing and vessel
rowth more slowly and not as effectively as CD34
rogenitors (19), perhaps because CD34 cells also include
EC populations, which (as previously discussed) appear to
ave more angiogenic potential. Different cell populations
ight also affect the function of each other, and their use in
ombination as “angiogenic therapy” may be more effective
han using isolated populations alone (20). Of note, the
resence of a CD34/CD133/CD14 subpopulation of
irculating EPCs has recently been demonstrated in periph-
ral blood (12).
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February 12, 2008:669–71 Editorial Commentuture Directions
he EPCs first described by Asahara et al. (1) that have
ttracted the most attention among researchers are essen-
ially monocyte-derived hematopoietic CD14 cells with
ariable expression of CD34, CD133, CD45, and KDR,
hich can form CFU-ECs and differentiate into macro-
hages (12,21). These cells do not incorporate into the
ascular endothelial monolayer but still support angiogene-
is. The current study by Sieveking et al. (7) is important
nd timely, given that it elegantly demonstrates—with a
ovel human EC-specific angiogenesis assay—that these
ind of cells do not directly participate in the formation of
ew vascular-like structures but strongly augment it in a
aracrine fashion.
The value of single or complex markers for different EPC
opulations still remains controversial and clearly reflects
he heterogeneous nature of endothelial precursors. Even
hough it is now known that OECs are derived from a small
D34/CD133/CD45/CD14 population, no strong
urface marker definition of OECs currently exists. As a
esult, marker estimations and culture properties have to be
sed by many researchers to define EPCs. Therefore, when
unctional properties of EPCs are evaluated in vitro, more
pecific approaches, such as the one proposed by Sieveking
t al. (7), should be employed.
Given novel data of morphology and biological properties
f different EPC subpopulations (22,23), the results of
arlier studies perhaps should be carefully re-examined, and
he impact of these subpopulations have to be taken into
onsideration when futures studies are performed. The types
f cells studied or used for such therapy have to be clearly
haracterized to avoid misleading results. Possible angio-
enic properties of EPCs should also be confirmed by
n vivo or in vitro angiogenic models. Clearly, the precise
iological role(s) of different EPCs alone or in combination
equire further clarification to open new avenues for cardio-
ascular therapy. We live in exciting times.
eprint requests and correspondence: Prof. Gregory Y. H. Lip,
ity Hospital NHS Trust, University Department of Medicine,
ity Hospital, Dudley Road, Birmingham B18 7QH, United
ingdom. E-mail: g.y.h.lip@bham.ac.uk.
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